Myo-inositol in Obese Pregnant Women

Myo-inositol May Prevent Gestational Diabetes in Obese Women

Myo-Inositol is classified as a member of the vitamin B complex. It is a constituent of living cells and is widespread in many food. It is involved in a number of biological processes, including insulin signal transduction, resulting in modulating insulin sensitivity. This is a prospective, randomized, double center, placebo-controlled study. Two hundred and twenty obese pregnant women will be included in the trial and, after an informed consent, will assume randomly 2 g of myo-inositol twice a day or placebo from 12-13th weeks gestation until delivery. Then,they will perform an Oral Glucose Tolerance Test (OGTT) at 24-28th weeks gestation. Records about delivery (gestational age, neonatal weight...) will be registered.

Inclusion Criteria:

• Obese pregnant women: BMI > 30 Kg/cm2
• first trimester fast glycaemia < 126 mg/dl
• single pregnancy

Exclusion Criteria:

• Pregnant women with BMI < 30 Kg/cm2
• first trimester fast glycaemia > 126 mg/dl
• previous gestational diabetes
• twin pregnancy
• pregestational diabetes
• associated therapies with corticosteroids